Targeted therapy for metastatic colorectal cancer

Abstract

Recent statistical data suggest that there is a rise in morbidity and mortality rates of colorectal cancer, which in conjunction with the prevalence of its metastatic forms and common dissemination presents a serious medical problem. The paper gives the data of multicenter clinical trials of the most effective targeted drugs, such as bevacizumab and cetuximab, in the treatment of colorectal cancer. It considers possibilities for current antitumor therapy for metastatic colorectal cancer, by using three patient groups as an example.